Loading...
SPPI logo

Spectrum Pharmaceuticals, Inc.NasdaqCM:SPPI Rapporto sulle azioni

Cap. di mercato US$209.9m
Prezzo delle azioni
n/a
Non disponibile
0
1Y17.0%
7D5.3%
1D
Valore del portafoglio
​
Vista

Spectrum Pharmaceuticals, Inc.

Report azionario NasdaqCM:SPPI

Capitalizzazione di mercato: US$209.9m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Spectrum Pharmaceuticals (SPPI) Panoramica del titolo

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. Maggiori dettagli

SPPI analisi fondamentale
Punteggio fiocco di neve
Valutazione6/6
Crescita futura5/6
Prestazioni passate0/6
Salute finanziaria3/6
Dividendi0/6

Premi

Negoziato a 82.9% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 67.27% all'anno

Negoziato a un buon valore rispetto ai pari e al settore

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 22.3%

Analisi del rischio

Ha meno di 1 anno di pista di cassa

Gli azionisti sono stati diluiti nell'ultimo anno


SPPI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Spectrum Pharmaceuticals, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Spectrum Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$1.03
Massimo di 52 settimaneUS$1.57
Minimo di 52 settimaneUS$0.32
Beta2.14
Variazione di 1 mese4.54%
Variazione a 3 mesi-1.90%
Variazione di 1 anno17.05%
Variazione a 3 anni-71.39%
Variazione a 5 anni-95.10%
Variazione dall'IPO-99.25%

Notizie e aggiornamenti recenti

Recent updates

Articolo di analisi • May 14

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Shareholders in Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) may be thrilled to learn that the analysts have just...
Articolo di analisi • May 12

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) investors will be delighted, with the company turning in some strong...
Seeking Alpha • Sep 20

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

US FDA scientists are concerned about the data Spectrum Pharmaceuticals (NASDAQ:SPPI) has provided to support its drug poziotinib for non-small cell lung cancer ahead of an advisory committee meeting on Thursday. Shares are down 28% in Tuesday morning trading. In a briefing document, the FDA scientists state the data provided shows a low overall response rate (ORR) with minimal duration of response (DOR). ORR was 28% while median DOR was 5.1 months. In addition, they say the safety profile is poor in that at the proposed dosage, 57% of patients experienced dose reductions and 85% of patients had grade 3-4 adverse events. Also, the FDA team faults Spectrum (SPPI) for what it calls inadequate dosage optimization since the company has proposed two different doses for accelerated approval and the planned confirmatory trial. "Confirmation of benefit will be significantly delayed given that confirmatory trial has not begun enrolling patients." Poziotinib is an oral tyrosine kinase inhibitor that inhibits the activity of epidermal growth factor receptor (EGFR [HER1], HER2, and HER4) kinases. Seeking Alpha's Quant Rating views Spectrum (SPPI) as a hold.
Articolo di analisi • Sep 16

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 09

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock jumped 10.4% afterhours on Friday after the U.S. Food and Drug Administration approved its Rolvedon injection. The injection is used to treat chemotherapy-induced neutropenia (abnormally low count of a type of neutrophils). SPPI said the FDA's nod marks the first novel long-acting GCSF (LA-GCSF) product approval in over 20 years. The company plans to commercially launch the injection in Q4. Shares of SPPI have fallen 18.2% YTD.
Seeking Alpha • Aug 21

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

We are circling back on a small biopharma named Spectrum Pharmaceuticals for the first time in a year and a half today. Spectrum has turned into a soap opera since then with two departures from the C-Suite, a CRL, and a significant workforce reduction. However, the company still is pushing two compounds towards potential FDA approval this year. An investment analysis follows in the paragraphs below. "Even as a solid rock is unshaken by the wind, so are the wise unshaken by praise or blame."― Dhammapada We last posted an article on Spectrum Pharmaceuticals (SPPI) back in March of 2021. At that time, we declined any investment recommendation on the shares but did promise to circle back on this name as its story developed. The company reported second-quarter results earlier this month and I have gotten a question or two from Seeking Alpha followers recently. Therefore, we will revisit this small biopharma company via the analysis below. Seeking Alpha Company Overview: Spectrum Pharmaceuticals focuses on developing and commercializing novel and targeted drug products with a primary focus in oncology. The company is headquartered just outside of Las Vegas. The stock currently trades around $1.25 a share and sports an approximate market capitalization of $250 million. Recent Developments: The company has been a non-stop soap opera since we last looked in on it. Its primary asset is ROLONTIS (eflapegrastim). Spectrum had submitted a marketing application on it for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs. This candidate has had a rocky ride, to say the least, towards FDA approval. First, the inspection of the manufacturing facility where ROLONTIS was to be made in South Korea by partner Hanmi was delayed thanks to the pandemic. March Company Presentation Then in August of 2021, the FDA slapped Spectrum's Biologics License Application or BLA with a Complete Response Letter or CRL. The CRL cited deficiencies related to manufacturing and indicated that a re-inspection will be necessary. Then in December of last year, the company announced its CEO was retiring which was followed by resignation of its CFO in February of this year. In between those management losses, Spectrum announced a restructuring that resulted in approximately 30% of its workforce being let go. The company also halted development of early-stage drug candidates to focus solely on pushing poziotinib and ROLONTIS across the finish line. These measures were projected to reduce annual cash burn by 20% to 25% and push the company's 'cash runway' into 2023. The company did resubmit its BLA for ROLONTIS in April and the FDA is scheduled to make a decision on its application on September 9th. January 2021 Company Presentation The FDA completed re-inspection of the manufacturing facility for ROLONTIS in August. Chemo-induced neutropenia impacts just over one million individuals in the United States. ROLONTIS would be the first drug in its class approved for this indication since Neulasta got the green light from the FDA in 2002. March Company Presentation March Company Presentation The approval path for poziotinib has been much smoother to this point. The compound is targeting patients with previously treated, locally advanced or metastatic non-small cell lung cancer, harboring HER2 exon 20 insertion mutations. This drug candidate is an orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. Poziotinib has fast track designation and is on an accelerated approval pathway for this indication. The NDA was submitted some ago has a PDUFA date of November 24th of this year. It is important to note Poziotinib has a much smaller potential market than ROLONTIS and the company will have to demonstrate the compound has an overall risk benefit and clinical relevance based on its 'ZENITH' study to the FDA to garner approval. A randomized confirmatory trial is currently ongoing. A critical phase 2 trial in 2nd line NSCLC patients with EGFR exon 20 mutations around Poziotinib did not meet its primary endpoint of ORR in one of its cohorts early in 2020. Analyst Commentary & Balance Sheet: Since second quarter results posted, B. Riley Financial ($4 price target), H.C. Wainwright ($10 price target) and JMP Securities ($4 price target) have all reiterated Buy ratings on SPPI.
Seeking Alpha • Aug 10

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals (NASDAQ:SPPI) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.10 (+60.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 2 years, SPPI has beaten EPS estimates 38% of the time and has beaten revenue estimates 13% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward.
Articolo di analisi • Jun 04

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 25

Spectrum Pharmaceuticals: Some Last Words

A spate of bad luck has destroyed SPPI stock. CEO and CFO have both resigned. Even if, somehow, ROLONTIS gets approved, they don't have the cash to commercialize.
Articolo di analisi • Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 12

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

SPPI received a surprise CRL for rolontis. This could be resolved before the year is out, but there is no real clarity. The company does have enough cash to last it for a year or more.
Seeking Alpha • Jul 29

Spectrum's Big Approval: Any Day Now

The FDA completed the inspection of Hanmi's Korean facility almost a month ago. Approval should happen any day now. Rolontis is targeting a $3bn+ market.
Articolo di analisi • May 31

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Feb 12

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Dec 21

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

A look at the shareholders of Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) can tell us which group is most powerful...

Rendimenti per gli azionisti

SPPIUS BiotechsUS Mercato
7D5.3%-1.6%-0.8%
1Y17.0%34.4%27.1%

Ritorno vs Industria: SPPI ha superato il US Biotechs che ha restituito 34.4 % nell'ultimo anno.

Rendimento vs Mercato: SPPI ha superato il mercato US che ha restituito 27.1 % nell'ultimo anno.

Volatilità dei prezzi

Is SPPI's price volatile compared to industry and market?
SPPI volatility
SPPI Average Weekly Movement7.2%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di SPPI è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale di SPPI è diminuita da 15% a 7% nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
198786Tom Rigawww.sppirx.com

Spectrum Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Spectrum Pharmaceuticals con la sua capitalizzazione di mercato?
SPPI statistiche fondamentali
Capitalizzazione di mercatoUS$209.89m
Utili (TTM)-US$67.71m
Ricavi(TTM)US$25.73m
8.2x
Rapporto P/S
-3.1x
Rapporto P/E

SPPI è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
SPPI Conto economico (TTM)
RicaviUS$25.73m
Costo del fatturatoUS$2.86m
Profitto lordoUS$22.87m
Altre speseUS$90.58m
Utili-US$67.71m

Ultimi utili riportati

Mar 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)-0.33
Margine lordo88.90%
Margine di profitto netto-263.16%
Rapporto debito/patrimonio netto107.6%

Come si è comportato SPPI nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2023/08/02 19:43
Prezzo dell'azione a fine giornata2023/07/31 00:00
Utili2023/03/31
Utili annuali2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Spectrum Pharmaceuticals, Inc. è coperta da 9 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David BuckB. Riley Securities, Inc.
Alethia YoungCantor Fitzgerald & Co.
Reni BenjaminCitizens JMP Securities, LLC